2024
Chapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.ChaptersRenal cell carcinomaCell carcinomaOrgan-confined renal cell carcinomaKidney cancerMetastatic renal cell carcinomaLong-term survival outcomesLandscape of renal cell carcinomaDiagnosis of kidney cancerRenal tubule epithelial cellsTubule epithelial cellsGroup of diseasesSurgical resectionSystemic therapyDistant metastasisSurvival outcomesDiagnosed patientsEpithelial cellsPatientsPatient deathGenetic landscapeCarcinomaDiseaseCancerResectionMetastasis
2023
Predictive Biomarkers in Advanced Renal Cell Carcinoma
Shinder B, Kronstedt S, Hakimi A. Predictive Biomarkers in Advanced Renal Cell Carcinoma. 2023, 251-268. DOI: 10.1007/978-3-031-40901-1_11.ChaptersRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaPredictive biomarkersEra of treatment optionsCharacteristics of renal cell carcinomaPrediction of treatment responseOptimal therapeutic pathwayTargeted systemic therapyImmuno-oncology agentsRoutine clinical useSystemic therapyAdvanced diseaseClinical benefitTreatment responseTreatment optionsClinical useTherapeutic pathwaysCarcinomaPatientsBiomarkersMolecular characteristicsTherapyChromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation
Lichtbroun B, Shinder B, Sara T, Srivastava A, Saraiya B, Mayer T, Cristelli R, Sadimin E, Weiss R, Singer E. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation. Journal Of Kidney Cancer And VHL 2023, 10: 1-8. PMID: 37441361, PMCID: PMC10334999, DOI: 10.15586/jkcvhl.v10i3.254.Peer-Reviewed Case Reports and Technical NotesChromophobe renal cell carcinomaSarcomatoid differentiationRenal cell carcinomaCell carcinomaClinical courseCases of ChRCCSystemic treatment optionsAggressive clinical courseMetastatic diseaseOverall survivalFavorable prognosisLarger tumorsClinicopathological dataPoor prognosisTreatment optionsPoor outcomeKidney cancerChRCCCarcinomaPrognosisDifferentiationSarcomatoidChromophobeTumorPatientsFactors associated with clinical trial participation for patients with renal cell carcinoma
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, Saraiya B, Ghodoussipour S, Singer E. Factors associated with clinical trial participation for patients with renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2023, 41: 208.e1-208.e8. PMID: 36868881, PMCID: PMC10106382, DOI: 10.1016/j.urolonc.2023.01.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaClinical trial participationClinical trialsOverall survivalClinical stageTrial patientsTrial participantsCharlson-Deyo comorbidity scoreAssociated with trial participationCompare overall survivalNational Cancer DatabaseLog-rank testClinical trial patientsPatient sociodemographic factorsAssociated with clinical trial participationMedian OSSuperior OSCancer DatabaseOncology clinical trialsSurvival outcomesMale patientsCase-control designPatient cohortControl cohort
2022
Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature
Cahill E, Tabakin A, Shinder B, Bramwit M, Saraiya B, Xu X, Salazar C, Zhou Z, Singer E. Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer And VHL 2022, 9: 32-38. PMID: 36118793, PMCID: PMC9431006, DOI: 10.15586/jkcvhl.v9i2.229.Peer-Reviewed Case Reports and Technical NotesRenal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature
Yoshitake S, Shinder B, Dazen K, Smith C, Mayer T, Sadimin E, Singer E. Renal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer And VHL 2022, 9: 22-26. PMID: 36118790, PMCID: PMC9430971, DOI: 10.15586/jkcvhl.v9i2.212.Peer-Reviewed Case Reports and Technical NotesFactors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original ResearchConceptsStage IV RCCMetastatic renal cell carcinomaNational Cancer DatabasePalliative interventionsRenal cell carcinomaMetastatic RCCClinical factorsCell carcinomaMultivariable logistic regression modelComprehensive cancer programsQuality of lifeLogistic regression modelsSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusOncologic careInsurance statusCancer DatabaseCancer programsEarly initiationIntervention utilizationTreatment-specific mannerPatientsPI use
2021
MP19-08 DISPARITIES IN CLINICAL TRIAL PARTICIPATION FOR PATIENTS WITH RENAL CELL CARCINOMA AND PROSTATE CANCER
Shinder B, Kim S, Patel H, Mayer T, Saraiya B, Jang T, Kim I, Singer E. MP19-08 DISPARITIES IN CLINICAL TRIAL PARTICIPATION FOR PATIENTS WITH RENAL CELL CARCINOMA AND PROSTATE CANCER. Journal Of Urology 2021, 206: e330-e330. DOI: 10.1097/ju.0000000000002004.08.Peer-Reviewed Original Research
2020
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
Srivastava A, Patel HV, Kim S, Shinder B, Sterling J, Tabakin AL, Polotti CF, Saraiya B, Mayer T, Kim IY, Ghodoussipour S, Patel HD, Jang TL, Singer EA. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars And Original Investigations 2020, 39: 247-257. PMID: 33223368, PMCID: PMC7574787, DOI: 10.1016/j.urolonc.2020.10.012.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaUpstaging riskOverall survivalCell carcinomaNonclear cell renal cell carcinomaOrgan-confined renal cell carcinomaCox proportional hazards modelNational Cancer DatabaseCell renal cell carcinomaKaplan-Meier curvesProportional hazards modelSmall renal massesCOVID-19Logistic regression modelsPT3a upstagingDelaying surgeryPrimary endpointSecondary endpointsPatient comorbiditiesMeier curvesElective surgeryRadical nephrectomyTumor histologyClinical stageRCC patientsChallenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery.
Patel H, Shinder B, Srinivasan R, Singer E. Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Current Opinion In Oncology 2020, 32: 240-249. PMID: 32195679, PMCID: PMC9788417, DOI: 10.1097/cco.0000000000000621.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellChemotherapy, AdjuvantClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCytoreduction Surgical ProceduresHumansKidney NeoplasmsNeoadjuvant TherapyNeoplasm MetastasisProtein Kinase InhibitorsRandomized Controlled Trials as TopicConceptsMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaBiology of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaManagement of metastatic renal cell carcinomaTyrosine kinase inhibitor cabozantinibProgrammed cell death protein 1 antibodyIntroduction of novel therapiesCombination of axitinibFirst-line therapyUS Food and Drug AdministrationFood and Drug AdministrationCytoreductive surgeryAdvanced RCCSystemic therapyCombination therapySurvival benefitTargeted therapyPatient selectionTreatment paradigmNovel therapiesTherapeutic advancesCombinatorial therapyTreatment advances
2018
Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database
Farber NJ, Rivera-Núñez Z, Kim S, Shinder B, Radadia K, Sterling J, Modi PK, Goyal S, Parikh R, Mayer TM, Weiss RE, Kim IY, Elsamra SE, Jang TL, Singer EA. Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2018, 37: 26-32. PMID: 30446458, PMCID: PMC6295174, DOI: 10.1016/j.urolonc.2018.10.004.Peer-Reviewed Original ResearchConceptsLymph node dissectionNonmetastatic renal cell carcinomaRenal cell carcinomaMedian overall survivalNational Cancer DatabaseOverall survivalCell carcinomaCancer DatabasePropensity score-weighted analysisLow-stage diseaseLN-positive patientsLymph node involvementCox regression analysisSubgroup of patientsT stages 1Contemporary practice patternsRegression analysisChi-square testOS benefitPotential overutilizationNode dissectionUnderwent surgeryNode involvementPatient demographicsPositive patientsRole of the androgen signaling axis in genitourinary malignancies.
Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research 2018, 7: 1135-1142. PMID: 30701159, PMCID: PMC6349041, DOI: 10.21037/tcr.2018.03.41.Peer-Reviewed Original ResearchRenal cell carcinomaGenitourinary malignanciesAndrogen receptorBladder cancerRole of ARAdvanced disease stateProstate cancer developmentNovel therapeutic strategiesCell carcinomaTherapeutic armamentariumTherapeutic strategiesMortality rateCancer developmentMalignancyAndrogensDisease statesCancerCarcinomaProstateArmamentariumMolecular biologyDiseaseProgressionRoleReceptors
2017
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach
Shinder B, Rhee K, Farrell D, Farber N, Stein M, Jang T, Singer E. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Frontiers In Oncology 2017, 7: 107. PMID: 28620578, PMCID: PMC5449498, DOI: 10.3389/fonc.2017.00107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMetastatic renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaSurgical managementSurgical management of patientsImmune checkpoint inhibitorsNeoadjuvant systemic therapyMetastatic kidney cancerCytokine-based immunotherapyOptimal patient selectionManagement of patientsCheckpoint inhibitorsCytoreductive surgeryMetastatic diseasePrimary tumorAdjuvant therapyProspective trialsTherapeutic armamentariumPatient selectionKidney cancerTherapyCarcinomaSurgeryPatients